SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
about
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.Semi-automated cancer genome analysis using high-performance computing.Chronic lymphocytic leukaemia genomics and the precision medicine era.Roles of SAMHD1 in antiviral defense, autoimmunity and cancer.SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination.SAMHD1 is a barrier to antimetabolite-based cancer therapies.Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and MetabolismSAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axisLow-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
P2860
Q33878949-DD7D7CAB-B14E-4D96-ADDF-AFC9F7695314Q38734230-75B44612-D154-44FA-AAFB-E6F050B6E6BBQ39263974-47903ABC-7B19-42A3-BFF1-97FF31B75CD1Q39264008-BFD0BCB6-28F6-43D9-A38B-D790B71D686AQ40082412-E36A83F4-6403-4BCA-83EC-2AA03479130CQ40246651-92A1B348-6A15-413E-83BA-4161EFB086CDQ41919532-259B12CE-CFA2-4E87-8876-784C54ED59F5Q48352256-16CE1F27-CD05-4761-813C-DF43EBD407A9Q48515407-216C6374-0F54-4C27-842A-DCD5B817ECBDQ49910540-2E354C1A-718B-4D6A-81F6-7163E9F679CAQ52431745-984E724C-E43A-4D55-8338-68DE5F93E607Q55283900-DD22EB4B-0531-402B-B26D-2BBED35E265DQ57175017-BE4A0337-B449-4E82-A001-AD4032FDDD4EQ57275043-A1E52E22-6A97-480B-A9B1-7E09AD4C335EQ57809333-85DC0AD6-4DFA-4531-8CE0-2A73904208C3
P2860
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@ast
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@en
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@nl
type
label
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@ast
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@en
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@nl
prefLabel
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@ast
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@en
SAMHD1 is a biomarker for cyta ...... get in acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
SAMHD1 is a biomarker for cyta ...... rget in acute myeloid leukemia
@en
P2093
Anjali Cremer
Christoph Schliemann
Constanze Schneider
Dominique Thomas
Eva Wardelmann
Gerd Geisslinger
Hanibal Bohnenberger
Julian Lohmeyer
Lena Stegmann
Margarethe Martin
P2860
P2888
P304
P356
10.1038/NM.4255
P407
P50
P577
2016-12-19T00:00:00Z